Analyzing the Development of Vaccines for Flavivirus-Endemic Scenarios: The Case of Dengue and Dengue Vaccine in Peru

TO THE EDITOR—

We read with great interest the phase 1 clinical trial published by Durbin and colleagues in the Journal of Infectious Diseases [1] in which a new tetravalent vaccine (TV003) proved to be safe with a balanced immunogenic response for the 4 serotypes of Dengue virus (DENV) in a North American adult population seronegative for DENV, yellow fever (YF), and other flaviviruses, including West Nile virus. These positive results and the promising single-dose regimen are exciting. We look forward to seeing the results of future studies with this candidate vaccine and its potential benefits to endemic areas like Peru [2, 3]

Authors: Ruiz-Alejos, Andrea; Navarro Huaman, Laura; Segura, Eddy R.
Source: The Journal of Infectious Diseases (JID)
URL: http://hdl.handle.net/10757/333606